| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
NF-κB (nuclear factor kappa B) – inhibition of NF-κB-dependent transactivation. IC50 = 6.1 μg/mL. [3]
|
|---|---|
| ln Vitro |
When LPS/IFN-gamma stimulates RAW 264.7 macrophages, moslosooflavone can dramatically reduce NF-kappaB's transcriptional activity [2].
- Moslosooflavone (compound 1) significantly inhibited NF-κB transcriptional activity in LPS/IFN-γ stimulated RAW 264.7 macrophages, with an IC50 value of 6.1 μg/mL. [3] - At concentrations of 5 and 10 μg/mL, Moslosooflavone significantly decreased TNF-α secretion from LPS/IFN-γ stimulated RAW 264.7 cells (545 ± 50 pg/mL and 300 ± 1 pg/mL, respectively) compared to the LPS/IFN-γ treated group (968 ± 0 pg/mL). [3] - The compound significantly decreased IL-6 production at 10 μg/mL (0.52 ± 0.19 ng/mL) compared to the control (0.78 ± 0.04 ng/mL); no significant inhibition was observed at lower concentrations (1.25, 2.5, 5 μg/mL). [3] - Moslosooflavone significantly decreased MIP-2 (macrophage inflammatory protein-2) secretion in a dose-dependent manner: at 2.5 μg/mL (0.82 ± 0.10 ng/mL), 5 μg/mL (0.43 ± 0.05 ng/mL), and 10 μg/mL (0.34 ± 0.02 ng/mL) compared to the control (1.15 ± 0.14 ng/mL). [3] - The compound significantly decreased nitric oxide (NO) production at 5 μg/mL (6.95 ± 1.98 μM) and 10 μg/mL (3.25 ± 0.35 μM) compared to the LPS/IFN-γ treated group (10.4 ± 0.88 μM). [3] - Significant correlations were observed between NF-κB-dependent luciferase activity and TNF-α (r = 0.56, P < 0.05), MIP-2 (r = 0.75, P < 0.01), and NO (r = 0.69, P < 0.01) productions. [3] |
| Cell Assay |
- NF-κB-dependent luciferase reporter assay: RAW 264.7 macrophages were seeded in 24-well plates at 5 × 10⁴ cells/well. Cells were co-transfected with 0.3 μg of 3x-κB-tk-luc reporter plasmid (containing three copies of an NF-κB binding site) and 0.1 μg of Renilla luciferase reporter plasmid pRL-tk using an in vitro transfection reagent. After 48 h, cells were preincubated with various concentrations of Moslosooflavone (or helenalin as a positive control) for 1 h, then stimulated with LPS (100 ng/mL) plus IFN-γ (1000 units/mL) for 8 h. Luciferase activity was measured using the Dual-Glo Luciferase reporter assay system. Cell viability was confirmed by MTT assay, showing no cytotoxicity at the concentrations used. [3]
- Cytokine (TNF-α, IL-6, MIP-2) measurement: After the above treatment, cell supernatants were collected. TNF-α, IL-6, and MIP-2 concentrations were determined using commercial ELISA kits according to the manufacturer’s protocols. [3] - NO determination: Nitric oxide production was measured using the Griess assay. Briefly, 50 μL of cell supernatant was incubated with 50 μL of Griess reagent (1% sulfanilamide in 2.5% phosphoric acid mixed 1:1 with 0.1% N-1-naphthylethylenediamine dihydrochloride in 2.5% phosphoric acid) in a 96-well plate for 10 min. Absorbance was read at 540 nm, and NO concentrations were determined using a standard curve. [3] |
| References |
|
| Additional Infomation |
5-hydroxy-7,8-dimethoxyflavonoids have reportedly been found in slender aphids, closely related aphids, and other organisms with available data.
Moslosooflavone (5-hydroxy-7,8-dimethoxyflavone) is a flavonoid isolated from Andrographis paniculata. In this study, its chemical structure was identified by comparison with published physical data. It belongs to one of three categories of active compounds from AP (flavonoids, steroids, diterpenoids). The IC50 value for inhibition of NF-κB transactivation (6.1 μg/mL) indicates it is a more effective inhibitor than the major diterpenoids 14-deoxy-11,12-didehydroandrographolide (7) and andrographolide (8). [3] |
| Molecular Formula |
C17H14O5
|
|---|---|
| Molecular Weight |
298.2901
|
| Exact Mass |
298.084
|
| CAS # |
3570-62-5
|
| PubChem CID |
188316
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
532.9±50.0 °C at 760 mmHg
|
| Melting Point |
182-183℃
|
| Flash Point |
200.6±23.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.622
|
| LogP |
2.52
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
440
|
| Defined Atom Stereocenter Count |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3524 mL | 16.7622 mL | 33.5244 mL | |
| 5 mM | 0.6705 mL | 3.3524 mL | 6.7049 mL | |
| 10 mM | 0.3352 mL | 1.6762 mL | 3.3524 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA